P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
Gabriella Scarlatti(Istituti di Ricovero e Cura a Carattere Scientifico), Terri Wrin, Saladi Osmanov(Joint United Nations Programme on HIV/AIDS), Hanneke Schuitemaker(Johnson & Johnson (Israel)), Marianne Jansson(Lund University), Lynn Morris(National Health Laboratory Service), Victoria R. Polonis(Henry M. Jackson Foundation), Leo Heyndríckx, Mauro Malnati(Vita-Salute San Raffaele University), José Alcamı́(Apple (Israel)), Quentin J. Sattentau(University of Oxford), Vera Bongertz(Faculdades Oswaldo Cruz), Christiane Moog(Inserm), Alan Heath(Iziko Museums of South Africa), Meghna Ramaswamy(National Institute for Biological Standards and Control), E Fenyö, Lucia Lopalco(Vita-Salute San Raffaele University), H. Holmes(National Institute for Biological Standards and Control), David C. Montefiori(Duke University)
Cited by 2
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
|Proceedings of the National Academy of Sciences|2003|1.2k